Thank you for sharing!

Your article was successfully shared with the contacts you provided.

Welcome to Skilled in the Art. I’m Law.com IP reporter Scott Graham. When I was relatively new to IP 3.5 years ago, I wrote about hedge fund manager Kyle Bass’ attempt to use PTAB petitions to short the stock of Acorda Pharmaceuticals. The petitions caused the stock to dip about 10 percent, but Acorda recovered and the PTAB ultimately turned away Bass’ challenge. Now Teva, Mylan and Roxane Labs have invalidated the patents in court, and we’ve got controversy again, this time over whether a “blocking patent” can negate secondary considerations of non-obviousness such as commercial success. I’ve got all the details below. Thanks to all of you who suggested ideas this week. There were a few I couldn’t get to but I’ve got one more newsletter this week. In the meantime, feel free to email me your thoughts and feedback and follow me on Twitter.

This premium content is locked for
Law.com subscribers only.

*May exclude premium content
Already have an account?
Interested in customizing your subscription with Law.com All Access?
Contact our Sales Professionals at 1-855-808-4530 or send an email to groupsales@alm.com to learn more.

Scott Graham

Scott Graham focuses on intellectual property and the U.S. Court of Appeals for the Federal Circuit. He writes ALM's Skilled in the Art IP briefing. Contact him at sgraham@alm.com.

More from this author


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2019 ALM Media Properties, LLC. All Rights Reserved.